Adenoid cystic carcinoma

Remix Therapeutics™ to Present Preclinical Data Demonstrating Anti-Tumor Activity of REM-422 in AML at the European Hematology Association (EHA) 2024 Congress

Retrieved on: 
木曜日, 6月 13, 2024
PDX, MYB, MDS, Cancer, EHA, ACC, RNA, Therapy, AML, CDX, Messenger, Adenoid cystic carcinoma, Disease, Acute myeloid leukemia, Lymphoma, Entrepreneurship, European Hematology Association, Syndrome, Vaccine

WATERTOWN, Mass., June 13, 2024 /PRNewswire/ -- Remix Therapeutics (Remix), a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and address underlying drivers of disease, will deliver a poster presentation demonstrating the therapeutic potential of REM-422, a potent, selective, oral small molecule MYB mRNA degrader for the treatment of acute myeloid leukemia (AML), at the European Hematology Association (EHA) 2024 Hybrid Congress in Madrid, Spain.

Key Points: 
  • The poster presentation will include preclinical data from MYB-dependent AML cell lines and human leukemia xenograft models showing REM-422 is broadly active across various AML models.
  • Furthermore, REM-422 induces tumor regressions in cell line-derived xenograft (CDX) and patient-derived xenograft (PDX) models of AML at well-tolerated doses.
  • The dysregulation of MYB, an oncogenic transcription factor, has been linked to numerous cancers including AML, myelodysplastic syndromes (MDS) and lymphoma.
  • Details for the poster presentation are as follows:
    Title: REM-422, a potent, selective, oral small molecule mRNA degrader of the MYB oncogene, demonstrates anti-tumor activity in mouse xenograft models of AML

Kymera Therapeutics Presents New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting

Retrieved on: 
土曜日, 6月 1, 2024
MD, Aes, Șaeș, Biomarker, ASCO, Uveal melanoma, Fatigue, Toxicity, Carcinoma, Melanoma, Plasma, Patient, Diarrhea, Annual general meeting, ACC, Neutropenia, Acute leukemia, Safety, MD Anderson Cancer Center, Resource, Society, DL2, Therapy, ALL, Appetite, AML, Arm, Thrombocytopenia, MDM2, DL, Arthralgia, Messenger, Adenoid cystic carcinoma, Lymphoma, Blood, Acute myeloid leukemia, CDKN1A, PD, TPD, MPN, Grade 3, Merkel-cell carcinoma, MCC, University, Poster, Therapeutic index, Nausea, Pharmaceutical industry

WATERTOWN, Mass., June 01, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today shared new clinical data from its ongoing KT-253 Phase 1 trial. KT-253, a potent, selective heterobifunctional small molecule degrader of MDM2, demonstrated preliminary signs of efficacy across tumor types at doses that were generally well-tolerated. The data were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place from May 31 – June 4, 2024. Results released in an ASCO poster today include a data cut-off of April 9, 2024.

Key Points: 
  • The data were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place from May 31 – June 4, 2024.
  • Results released in an ASCO poster today include a data cut-off of April 9, 2024.
  • “We’re encouraged by the data emerging from the KT-253 Phase 1 dose escalation trial, showcasing the potential of TPD to address this clinically proven but inadequately drugged cancer mechanism.
  • Kymera is also developing a biomarker-based patient selection strategy for subsequent development beyond Phase 1a and is expected to present data at a medical meeting this year.

Kymera Therapeutics to Present New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting

Retrieved on: 
木曜日, 5月 23, 2024
Uveal melanoma, Patient, Headache, DL2, Carcinoma, Plasma, Acute myeloid leukemia, PD, Thrombocytopenia, Toxicity, ACC, Nausea, Black Majesty, Messenger, Pharmacodynamics, Therapy, Grade 3, Safety, Acute lymphoblastic leukemia, Arm, CDKN1A, MD, Blood, AML, Efficacy, MPN, ALL, Biomarker, ASCO, Șaeș, MDM2, Fatigue, Poster, Society, TPD, Adenoid cystic carcinoma, Aes, Merkel-cell carcinoma, Resource, Vomiting, MCC, DLT, Annual general meeting, Pharmaceutical industry

WATERTOWN, Mass., May 23, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced new clinical data for KT-253, a first-in-class MDM2 degrader, from its ongoing Phase 1 dose escalation trial will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place from May 31 – June 4, 2024, in Chicago, Illinois. Results released in an ASCO abstract today include a data cut-off of January 26, 2024.

Key Points: 
  • Results released in an ASCO abstract today include a data cut-off of January 26, 2024.
  • “We continue to see encouraging data from the trial’s dose escalation phase demonstrating potent upregulation of p53 biomarkers and signs of antitumor activity in patients.
  • The Company expects to complete the study and share additional clinical data to inform the program’s next development steps in 2024 at an upcoming medical meeting.
  • Kymera is also developing a biomarker-based patient selection strategy for subsequent development beyond Phase 1a and is expected to present data at a medical meeting this year.

Kronos Bio Reports First-Quarter 2024 Financial Results

Retrieved on: 
木曜日, 5月 9, 2024
CDK9, Investment, Research, KRON, Genentech, IND, ASCO, Therapy, Patient, Society, AACR, Adenoid cystic carcinoma, Cancer, SAN, Pharmaceutical industry

SAN MATEO, Calif. and CAMBRIDGE, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to developing small molecule therapeutics that address cancers and other diseases driven by deregulated transcription, today reported recent business progress and financial results for the first-quarter of 2024.

Key Points: 
  • SAN MATEO, Calif. and CAMBRIDGE, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to developing small molecule therapeutics that address cancers and other diseases driven by deregulated transcription, today reported recent business progress and financial results for the first-quarter of 2024.
  • R&D Expenses: Research and development expenses were $14.2 million for the first quarter of 2024, which includes non-cash stock-based compensation expense of $1.2 million.
  • Impairment of Long-lived Assets and Restructuring: The Company incurred impairment of long-lived assets expense of $6.6 million for the first quarter of 2024.
  • The Company also incurred restructuring expense of $6.2 million for the first quarter of 2024, which includes non-cash stock-based compensation of $4.4 million.

Kronos Bio To Present Three Posters at AACR 2024 Annual Meeting

Retrieved on: 
火曜日, 3月 5, 2024
SAN, IRF4, Senior, KRON, Research, Research and development, Adenoid cystic carcinoma, AACR, Molecular biology, Gene expression, Abstract, Multiple myeloma, CDK9, KAT, Development, Cancer, Pharmaceutical industry

SAN MATEO, Calif. and CAMBRIDGE, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that three abstracts have been selected for presentation at the American Association for Cancer Research (AACR) annual meeting, being held from April 5-10, 2024 in San Diego, California.

Key Points: 
  • SAN MATEO, Calif. and CAMBRIDGE, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that three abstracts have been selected for presentation at the American Association for Cancer Research (AACR) annual meeting, being held from April 5-10, 2024 in San Diego, California.
  • “We are excited to present our data at AACR showing that targeting p300’s enzymatic KAT domain can selectively downregulate IRF4, a long sought after transcription factor dependency in multiple myeloma.
  • Although p300 is an essential gene, our data show that through its relationship as a critical IRF4 cofactor, we can achieve selective antiproliferative effects against myeloma cells,” said Charles Lin, Ph.D., Senior Vice President, Research and Development of Kronos Bio.
  • Details for the AACR 2024 abstracts are as follows:
    Title: A dose escalation and cohort expansion study of the CDK9 inhibitor KB-0742 in relapsed, refractory and transcriptionally addicted solid tumors
    Title: KB-0742, an oral highly selective CDK9 inhibitor, demonstrates preclinical activity in transcription factor fusion driven adenoid cystic carcinoma patient-derived models
    Poster Session: Molecular Biology in Clinical Oncology: Characterizing and Modulating Epigenetics and Gene Expression

Vietnam Veteran marks holidays and birthdays at Cleveland Fisher House

Retrieved on: 
火曜日, 11月 28, 2023
Fisher House, Mask, Walking, Meal, Family, Cleveland Clinic, New Year's Day, Friends, Adenoid cystic carcinoma, Microwave, Cancer, Hatboro, Pennsylvania, Food, Fisher House (Hatboro, Pennsylvania), THANK, Radiation

David is a veteran who was diagnosed with cancer that necessitated almost two months of treatment in Cleveland.

Key Points: 
  • David is a veteran who was diagnosed with cancer that necessitated almost two months of treatment in Cleveland.
  • The couple spent the entirety of the 2020-2021 holiday season at the Cleveland Fisher House.
  • After meeting with a social worker, she suggested the Fisher House would be the best place for us to spend our 54 days in Cleveland.
  • It is very hard to express in words what the Fisher House has done for my husband and myself.

Ryvu Therapeutics Provides an Update on the Progress of RVU120 Phase I Studies in Patients with Solid Tumors and AML/HR-MDS, and Presents the Updated Development Plan for RVU120

Retrieved on: 
月曜日, 10月 23, 2023
Medulloblastoma, Bone marrow, Plasma, AUC, Acute myeloid leukemia, Cmax, ESMO, Erythropoiesis, Principal investigator, Aes, PD, Congress, MD, Adenoid cystic carcinoma, CEST, Ruxolitinib, Cell, Data, Syndrome, All-comers track meet, Phase, SD, Risk, Webcast, Pancreatic cancer, Venetoclax, NPM1, WSE, ADCC, Safety, European Society for Medical Oncology, Patient, AML, Sarcoma, Pharmaceutical industry, Medical imaging, Dietary supplement

The total budget for the Phase II clinical development of RVU120 aligns with the estimates initially announced in the Ryvu Development Plans for 2022-2024.

Key Points: 
  • The total budget for the Phase II clinical development of RVU120 aligns with the estimates initially announced in the Ryvu Development Plans for 2022-2024.
  • The presented RVU120 development plan aligns with the budget outlined in Ryvu Development Plans for 2022-2024 and targets multi-billion-dollar market potential.
  • At the ESMO Congress 2023, Ryvu announced updated clinical Phase I data from Phase I/II study of RVU120 in relapsed/refractory metastatic advanced solid tumors.
  • Ryvu will host a webinar today (Monday, October 23) at 9:00 am CEST to discuss further RVU120 development plans.

Research Conducted by Florida Cancer Specialists & Research Institute Featured at European Society of Medical Oncology 2023 Congress

Retrieved on: 
金曜日, 10月 20, 2023
Research, Annals of Oncology, ESMO, SERD, Physician, MAPK, Congress, European Society for Medical Oncology, Estate (law), Drug development, B7-H4, Adenoid cystic carcinoma, FIH, Abstract, Oncology, Safety, Cancer, FCS, ATR, Patient, Diagnosis, Conjugation, Pharmaceutical industry, MD

FORT MYERS, Fla., Oct. 20, 2023 /PRNewswire/ -- Research conducted by Florida Cancer Specialists & Research Institute, LLC (FCS) is featured this week among the latest advancements and findings in cancer care at the European Society of Medical Oncology (ESMO) Congress in Madrid, Spain. Five FCS physicians are the first authors and/or co-authors of 12 cancer research studies that will be shared at the global gathering of oncologists, researchers, patient advocates, pharmaceutical representatives and journalists. With more than 30,000 members from 168 countries worldwide, ESMO is the leading professional organization for medical oncology.

Key Points: 
  • FORT MYERS, Fla., Oct. 20, 2023 /PRNewswire/ -- Research conducted by Florida Cancer Specialists & Research Institute, LLC (FCS) is featured this week among the latest advancements and findings in cancer care at the European Society of Medical Oncology (ESMO) Congress in Madrid, Spain.
  • With more than 30,000 members from 168 countries worldwide, ESMO is the leading professional organization for medical oncology.
  • The ESMO Congress 2023 is a global stage for the exchange of potentially practice-changing data and multidisciplinary conversations that will spur transformative therapies against cancer.
  • All of the study abstracts will be published online in the ESMO Congress 2023 Abstract Book, a supplement to the official ESMO journal, Annals of Oncology.

Elevar Therapeutics Names Dr. Chris Galloway Vice President of Clinical Development

Retrieved on: 
火曜日, 8月 15, 2023
University, Moses Austin, Hepatocellular carcinoma, Diffusion Pharmaceuticals, Adenoid cystic carcinoma, DaVita Inc., Liver cancer, MD, Patient, Biology, Merck, PD-1, Hypoxia, Therapy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, UTHealth School of Dentistry, Food, Pharmaceutical industry

FORT LEE, N.J., Aug. 15, 2023 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and a fully integrated biopharmaceutical company dedicated to elevating treatment experiences and outcomes for patients who have limited or inadequate therapeutic options, today announced the hiring of Dr. Chris Galloway as vice president of clinical development.

Key Points: 
  • FORT LEE, N.J., Aug. 15, 2023 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and a fully integrated biopharmaceutical company dedicated to elevating treatment experiences and outcomes for patients who have limited or inadequate therapeutic options, today announced the hiring of Dr. Chris Galloway as vice president of clinical development.
  • At Elevar, he’ll lead a talented team of medical professionals developing the company’s current portfolio and play a key strategic role in identifying and driving new assets and indications.
  • “Elevar Therapeutics is currently active in all stages of clinical development and Dr. Chris Galloway’s breadth of experience makes him a perfect addition to our talented team,” said Elevar Chief Executive Officer Saeho Chong.
  • Galloway holds an MD from the University of Texas Medical Branch at Galveston and bachelor’s degree in biology from the University of Texas at Austin.

Ayala Pharmaceuticals Announces Second Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
木曜日, 8月 10, 2023
Columbia University, ACC, Plantar fibromatosis, Financial result, ESMO, Survival, Adenoid cystic carcinoma, ASCO, Congress, American Society of Clinical Oncology, Patient, OTCQX, Ayala, Security (finance), European Society for Medical Oncology, Research, FDA, Berlin, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, PSA, Society, Food, Prostate cancer, Pharmaceutical industry, Rare-earth element, Clothing

REHOVOT, Israel and MONMOUTH JUNCTION, N.J., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced second-quarter 2023 financial results and provided a corporate update.

Key Points: 
  • Definitive merger agreement with Biosight, expected to close near end of Q3 2023
    REHOVOT, Israel and MONMOUTH JUNCTION, N.J., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced second-quarter 2023 financial results and provided a corporate update.
  • Gain clarity on path for future development plan for AL101 in recurrent/metastatic adenoid cystic carcinoma (R/M ACC), expected in 2023.
  • Consolidated Financial Results for the Second Quarter Ended June 30, 2023
    Cash position On June 30, 2023, the Company’s consolidated cash and cash equivalents position was $7.1 million.
  • For further details on the Company’s financial results, including results for the six-month period ended June 30, 2023, refer to our quarterly report on Form 10-Q for the quarter ended June 30,2023, filed with the Securities and Exchange Commission.